- Home
- ACAD vs DOOO Comparison
ACAD vs DOOO Comparison
Compare ACAD & DOOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- DOOO
- Stock Information
- Founded
- ACAD 1993
- DOOO 1937
- Country
- ACAD United States
- DOOO Canada
- Employees
- ACAD N/A
- DOOO N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- DOOO
- Sector
- ACAD Health Care
- DOOO
- Exchange
- ACAD Nasdaq
- DOOO Nasdaq
- Market Cap
- ACAD 2.5B
- DOOO 2.7B
- IPO Year
- ACAD 2004
- DOOO N/A
- Fundamental
- Price
- ACAD $22.71
- DOOO $46.96
- Analyst Decision
- ACAD Buy
- DOOO Buy
- Analyst Count
- ACAD 16
- DOOO 5
- Target Price
- ACAD $27.00
- DOOO $43.00
- AVG Volume (30 Days)
- ACAD 1.6M
- DOOO 249.3K
- Earning Date
- ACAD 08-05-2025
- DOOO 05-29-2025
- Dividend Yield
- ACAD N/A
- DOOO 1.30%
- EPS Growth
- ACAD N/A
- DOOO N/A
- EPS
- ACAD 1.37
- DOOO N/A
- Revenue
- ACAD $996,283,000.00
- DOOO $5,555,499,267.00
- Revenue This Year
- ACAD $13.39
- DOOO N/A
- Revenue Next Year
- ACAD $10.59
- DOOO $5.67
- P/E Ratio
- ACAD $16.65
- DOOO N/A
- Revenue Growth
- ACAD 22.42
- DOOO N/A
- 52 Week Low
- ACAD $13.40
- DOOO $31.78
- 52 Week High
- ACAD $25.23
- DOOO $74.00
- Technical
- Relative Strength Index (RSI)
- ACAD 66.04
- DOOO 63.80
- Support Level
- ACAD $21.35
- DOOO $47.01
- Resistance Level
- ACAD $22.69
- DOOO $48.55
- Average True Range (ATR)
- ACAD 0.76
- DOOO 1.38
- MACD
- ACAD -0.13
- DOOO -0.12
- Stochastic Oscillator
- ACAD 70.76
- DOOO 53.73
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About DOOO BRP Inc. (Recreational Products) Common Subordinate Voting Shares
BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which is now being unwound (Manitou pontoon boats remain up for sale). At the end of fiscal 2025, the company sold its products through a network of more than 2,400 independent dealers and 140 distributors in around 130 countries.